Annual Net Income
$167.65 M
+$26.08 M+18.43%
31 December 2023
Summary:
BioMarin Pharmaceutical annual net profit is currently $167.65 million, with the most recent change of +$26.08 million (+18.43%) on 31 December 2023. During the last 3 years, it has fallen by -$686.38 million (-80.37%). BMRN annual net income is now -80.37% below its all-time high of $854.03 million, reached on 31 December 2020.BMRN Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
$106.08 M
-$1.09 M-1.02%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly net profit is currently $106.08 million, with the most recent change of -$1.09 million (-1.02%) on 30 September 2024. Over the past year, it has increased by +$65.70 million (+162.72%). BMRN quarterly net income is now -86.48% below its all-time high of $784.80 million, reached on 30 September 2020.BMRN Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
$322.29 M
+$65.70 M+25.61%
30 September 2024
Summary:
BioMarin Pharmaceutical TTM net profit is currently $322.29 million, with the most recent change of +$65.70 million (+25.61%) on 30 September 2024. Over the past year, it has increased by +$175.27 million (+119.21%). BMRN TTM net income is now -62.26% below its all-time high of $854.03 million, reached on 31 December 2020.BMRN TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +18.4% | +162.7% | +119.2% |
| 3 y3 years | -80.4% | +390.7% | +2871.5% |
| 5 y5 years | +317.1% | +92.8% | +857.9% |
BMRN Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -80.4% | +361.6% | -12.2% | +283.2% | at high | +603.0% |
| 5 y | 5 years | -80.4% | +317.1% | -86.5% | +283.2% | -62.3% | +603.0% |
| alltime | all time | -80.4% | +126.6% | -86.5% | +125.3% | -62.3% | +151.1% |
BioMarin Pharmaceutical Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $106.08 M(-1.0%) | $322.29 M(+25.6%) |
| June 2024 | - | $107.17 M(+20.9%) | $256.59 M(+24.9%) |
| Mar 2024 | - | $88.66 M(+335.2%) | $205.46 M(+22.6%) |
| Dec 2023 | $167.65 M(+18.4%) | $20.38 M(-49.5%) | $167.65 M(+14.0%) |
| Sept 2023 | - | $40.38 M(-27.9%) | $147.02 M(+47.0%) |
| June 2023 | - | $56.04 M(+10.2%) | $99.99 M(+39.6%) |
| Mar 2023 | - | $50.85 M(<-9900.0%) | $71.61 M(-49.4%) |
| Dec 2022 | $141.56 M(-320.9%) | -$249.00 K(-96.3%) | $141.56 M(+68.7%) |
| Sept 2022 | - | -$6.65 M(-124.0%) | $83.91 M(+55.2%) |
| June 2022 | - | $27.66 M(-77.1%) | $54.07 M(+37.4%) |
| Mar 2022 | - | $120.80 M(-308.6%) | $39.35 M(-161.4%) |
| Dec 2021 | -$64.08 M(-107.5%) | -$57.90 M(+58.7%) | -$64.08 M(-690.8%) |
| Sept 2021 | - | -$36.49 M(-382.0%) | $10.85 M(-98.7%) |
| June 2021 | - | $12.94 M(-25.5%) | $832.14 M(+5.3%) |
| Mar 2021 | - | $17.37 M(+2.0%) | $790.02 M(-7.5%) |
| Dec 2020 | $854.03 M(-3681.1%) | $17.03 M(-97.8%) | $854.03 M(+0.2%) |
| Sept 2020 | - | $784.80 M(-2789.2%) | $852.02 M(+596.9%) |
| June 2020 | - | -$29.18 M(-135.9%) | $122.26 M(+7.2%) |
| Mar 2020 | - | $81.38 M(+441.7%) | $114.01 M(-578.1%) |
| Dec 2019 | -$23.85 M(-69.1%) | $15.02 M(-72.7%) | -$23.85 M(-43.9%) |
| Sept 2019 | - | $55.04 M(-247.0%) | -$42.52 M(-61.4%) |
| June 2019 | - | -$37.44 M(-33.7%) | -$110.18 M(+23.1%) |
| Mar 2019 | - | -$56.47 M(+1447.2%) | -$89.53 M(+16.0%) |
| Dec 2018 | -$77.21 M(-34.0%) | -$3.65 M(-71.1%) | -$77.21 M(-38.2%) |
| Sept 2018 | - | -$12.62 M(-24.8%) | -$124.95 M(+0.1%) |
| June 2018 | - | -$16.79 M(-62.0%) | -$124.86 M(-13.8%) |
| Mar 2018 | - | -$44.15 M(-14.1%) | -$144.90 M(+23.8%) |
| Dec 2017 | -$117.04 M(-81.4%) | -$51.39 M(+310.2%) | -$117.04 M(-25.2%) |
| Sept 2017 | - | -$12.53 M(-66.0%) | -$156.37 M(-13.7%) |
| June 2017 | - | -$36.83 M(+126.1%) | -$181.27 M(-67.8%) |
| Mar 2017 | - | -$16.29 M(-82.0%) | -$563.45 M(-10.6%) |
| Dec 2016 | -$630.21 M(+266.8%) | -$90.72 M(+142.4%) | -$630.21 M(+33.8%) |
| Sept 2016 | - | -$37.42 M(-91.1%) | -$470.87 M(-10.2%) |
| June 2016 | - | -$419.01 M(+404.5%) | -$524.37 M(+179.9%) |
| Mar 2016 | - | -$83.05 M(-221.0%) | -$187.35 M(+9.1%) |
| Dec 2015 | -$171.80 M(+28.2%) | $68.62 M(-175.5%) | -$171.80 M(-44.6%) |
| Sept 2015 | - | -$90.93 M(+10.9%) | -$310.21 M(+46.4%) |
| June 2015 | - | -$81.99 M(+21.5%) | -$211.84 M(+29.7%) |
| Mar 2015 | - | -$67.50 M(-3.3%) | -$163.35 M(+21.9%) |
| Dec 2014 | -$133.97 M(-24.0%) | -$69.80 M(-1037.5%) | -$133.97 M(+6.2%) |
| Sept 2014 | - | $7.45 M(-122.2%) | -$126.16 M(-32.4%) |
| June 2014 | - | -$33.50 M(-12.1%) | -$186.63 M(+6.9%) |
| Mar 2014 | - | -$38.12 M(-38.5%) | -$174.66 M(-1.0%) |
| Dec 2013 | -$176.35 M(+54.2%) | -$61.99 M(+16.9%) | -$176.35 M(+5.4%) |
| Sept 2013 | - | -$53.02 M(+146.2%) | -$167.38 M(+39.8%) |
| June 2013 | - | -$21.53 M(-45.9%) | -$119.71 M(-8.0%) |
| Mar 2013 | - | -$39.81 M(-24.9%) | -$130.19 M(+13.9%) |
| Dec 2012 | -$114.35 M(+112.4%) | -$53.01 M(+889.6%) | -$114.35 M(+29.8%) |
| Sept 2012 | - | -$5.36 M(-83.3%) | -$88.07 M(-12.3%) |
| June 2012 | - | -$32.01 M(+33.5%) | -$100.37 M(+36.7%) |
| Mar 2012 | - | -$23.97 M(-10.3%) | -$73.44 M(+36.4%) |
| Dec 2011 | -$53.84 M | -$26.73 M(+51.4%) | -$53.84 M(+37.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | -$17.65 M(+247.7%) | -$39.29 M(-120.1%) |
| June 2011 | - | -$5.08 M(+16.2%) | $195.70 M(-2.3%) |
| Mar 2011 | - | -$4.37 M(-64.1%) | $200.30 M(-2.7%) |
| Dec 2010 | $205.82 M(<-9900.0%) | -$12.19 M(-105.6%) | $205.82 M(-7.6%) |
| Sept 2010 | - | $217.33 M(<-9900.0%) | $222.72 M(+1752.1%) |
| June 2010 | - | -$477.00 K(-141.4%) | $12.03 M(-13.0%) |
| Mar 2010 | - | $1.15 M(-75.6%) | $13.81 M(-2924.9%) |
| Dec 2009 | -$488.00 K(-101.6%) | $4.71 M(-29.1%) | -$489.00 K(-102.5%) |
| Sept 2009 | - | $6.64 M(+406.1%) | $19.31 M(+43.1%) |
| June 2009 | - | $1.31 M(-110.0%) | $13.49 M(-15.6%) |
| Mar 2009 | - | -$13.15 M(-153.7%) | $15.99 M(-48.1%) |
| Dec 2008 | $30.83 M(-295.1%) | $24.51 M(+2856.1%) | $30.83 M(+246.6%) |
| Sept 2008 | - | $829.00 K(-78.2%) | $8.89 M(+212.1%) |
| June 2008 | - | $3.81 M(+126.0%) | $2.85 M(-159.1%) |
| Mar 2008 | - | $1.69 M(-34.4%) | -$4.82 M(-69.5%) |
| Dec 2007 | -$15.80 M(-44.6%) | $2.57 M(-149.3%) | -$15.80 M(-45.1%) |
| Sept 2007 | - | -$5.22 M(+35.0%) | -$28.76 M(-6.0%) |
| June 2007 | - | -$3.86 M(-58.4%) | -$30.58 M(+9.1%) |
| Mar 2007 | - | -$9.29 M(-10.6%) | -$28.05 M(-1.7%) |
| Dec 2006 | -$28.53 M(-61.6%) | -$10.39 M(+47.7%) | -$28.53 M(-13.9%) |
| Sept 2006 | - | -$7.04 M(+431.0%) | -$33.14 M(-20.3%) |
| June 2006 | - | -$1.32 M(-86.5%) | -$41.58 M(-32.5%) |
| Mar 2006 | - | -$9.78 M(-34.8%) | -$61.59 M(-17.1%) |
| Dec 2005 | -$74.27 M(-60.4%) | -$15.00 M(-3.1%) | -$74.27 M(-47.6%) |
| Sept 2005 | - | -$15.48 M(-27.5%) | -$141.70 M(-9.0%) |
| June 2005 | - | -$21.34 M(-5.0%) | -$155.70 M(-18.0%) |
| Mar 2005 | - | -$22.46 M(-72.8%) | -$189.96 M(+1.3%) |
| Dec 2004 | -$187.44 M(+147.3%) | -$82.42 M(+179.6%) | -$187.44 M(+43.4%) |
| Sept 2004 | - | -$29.48 M(-47.0%) | -$130.75 M(+6.7%) |
| June 2004 | - | -$55.60 M(+178.8%) | -$122.56 M(+61.1%) |
| Mar 2004 | - | -$19.95 M(-22.5%) | -$76.06 M(+0.3%) |
| Dec 2003 | -$75.80 M(-2.1%) | -$25.73 M(+20.8%) | -$75.80 M(+9.2%) |
| Sept 2003 | - | -$21.29 M(+134.0%) | -$69.40 M(+6.4%) |
| June 2003 | - | -$9.10 M(-53.8%) | -$65.22 M(-7.5%) |
| Mar 2003 | - | -$19.68 M(+1.8%) | -$70.53 M(-8.9%) |
| Dec 2002 | -$77.46 M(+14.6%) | -$19.33 M(+13.0%) | -$77.45 M(-16.8%) |
| Sept 2002 | - | -$17.11 M(+18.7%) | -$93.05 M(+7.0%) |
| June 2002 | - | -$14.41 M(-45.8%) | -$86.95 M(+2.9%) |
| Mar 2002 | - | -$26.60 M(-23.8%) | -$84.51 M(+25.0%) |
| Dec 2001 | -$67.61 M(+80.9%) | -$34.92 M(+217.0%) | -$67.61 M(+56.9%) |
| Sept 2001 | - | -$11.02 M(-8.0%) | -$43.08 M(+7.1%) |
| June 2001 | - | -$11.97 M(+23.4%) | -$40.21 M(+13.8%) |
| Mar 2001 | - | -$9.70 M(-6.7%) | -$35.33 M(-5.4%) |
| Dec 2000 | -$37.36 M(+33.1%) | -$10.39 M(+27.6%) | -$37.36 M(+3.7%) |
| Sept 2000 | - | -$8.15 M(+15.0%) | -$36.04 M(+1.5%) |
| June 2000 | - | -$7.09 M(-39.6%) | -$35.49 M(+0.8%) |
| Mar 2000 | - | -$11.74 M(+29.4%) | -$35.21 M(+25.4%) |
| Dec 1999 | -$28.07 M(+128.2%) | -$9.07 M(+19.4%) | -$28.08 M(+47.7%) |
| Sept 1999 | - | -$7.60 M(+11.8%) | -$19.01 M(+66.6%) |
| June 1999 | - | -$6.80 M(+47.5%) | -$11.41 M(+147.5%) |
| Mar 1999 | - | -$4.61 M | -$4.61 M |
| Dec 1998 | -$12.30 M | - | - |
FAQ
- What is BioMarin Pharmaceutical annual net profit?
- What is the all time high annual net income for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual net income year-on-year change?
- What is BioMarin Pharmaceutical quarterly net profit?
- What is the all time high quarterly net income for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly net income year-on-year change?
- What is BioMarin Pharmaceutical TTM net profit?
- What is the all time high TTM net income for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical TTM net income year-on-year change?
What is BioMarin Pharmaceutical annual net profit?
The current annual net income of BMRN is $167.65 M
What is the all time high annual net income for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual net profit is $854.03 M
What is BioMarin Pharmaceutical annual net income year-on-year change?
Over the past year, BMRN annual net profit has changed by +$26.08 M (+18.43%)
What is BioMarin Pharmaceutical quarterly net profit?
The current quarterly net income of BMRN is $106.08 M
What is the all time high quarterly net income for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly net profit is $784.80 M
What is BioMarin Pharmaceutical quarterly net income year-on-year change?
Over the past year, BMRN quarterly net profit has changed by +$65.70 M (+162.72%)
What is BioMarin Pharmaceutical TTM net profit?
The current TTM net income of BMRN is $322.29 M
What is the all time high TTM net income for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high TTM net profit is $854.03 M
What is BioMarin Pharmaceutical TTM net income year-on-year change?
Over the past year, BMRN TTM net profit has changed by +$175.27 M (+119.21%)